
Cancer Immunotherapy Market Report 2024-2034
Description
Cancer Immunotherapy Market Report 2024-2034
The Cancer Immunotherapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Increasing Prevalence of Cancer and Increasing Research in Cancer Immunotherapy are driving the Market Growth
Cancer is a major cause of death worldwide, accounting for about 20 million new cancer cases and over 9 million deaths in 2022, according to data released by the World Health Organisation in February 2024. By 2040, the American Cancer Society, Inc. projects that the global cancer burden would have increased to over 28 million cases due to present and anticipated population ageing and growth. North America is fourth in terms of cancer deaths and fourth in terms of new cases, whereas China, which has the greatest population in the world, has the highest global proportion of both. The cancer burden may rise in the future due to factors such increased alcohol and tobacco use, poor diet, physical inactivity, and air pollution in many different parts of the world.
Modern cancer treatments, such as those based on immunotherapy, have revolutionised the field in recent years. One such treatment that has greatly excited researchers and oncologists is cancer immunotherapy. Globally, cancer immunotherapy is being used as a treatment for cancer after years of intensive research. For instance, the German biomedical research institute BioMed X and one of the biggest pharmaceutical corporations in Japan, Ono Pharmaceutical Co., Ltd., announced in December 2023 the commencement of a new cooperative research initiative. Using neutrophils' anticancer properties to create next-generation immunotherapies is the aim of this research endeavour. Therefore, the primary driver propelling the growth of this market is the ongoing research into how to improve immunotherapy and the ongoing development of novel immunotherapies for the treatment of cancer.
Reimbursement Challenges, High Cost and Side-effects may Hamper Cancer Immunotherapy Growth
Healthcare providers, insurance companies, and national and local government organisations all around the world have faced difficulties in getting reimbursement for cancer immunotherapy treatments. Cancer immunotherapy is one of the priciest medications available, costing more than $100,000 per patient. This covers the price of medications, hospital stays, and multiple days of intensive care because many patients receiving cancer immunotherapy treatments have serious adverse effects.
The Keytruda maker, Merck, states that the out-of-pocket expenses for each infusion might vary from $1,000 to $1,950. However, this rate can still be excessively expensive for many patients. In the event that the patient has Medigap or Medicare Advantage (Part C), additional coverage may be obtained. The Keytruda treatment may potentially be completely covered, depending on the plan. In actuality, 41% of patients with Medicare Advantage Plans reported having no out-of-pocket costs, according to Merck. Patients in developing nations cannot afford the high cost of immunotherapy medications. One of the main obstacles facing businesses developing immunotherapy medications is high pricing. Thus, it is one of the main factors impeding this market's growth over the predicted period.
What Questions Should You Ask Before Buying a Market Research Report?
- How is the cancer immunotherapy market evolving?
- What is driving and restraining the cancer immunotherapy market?
- How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each cancer immunotherapy submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading cancer immunotherapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the cancer immunotherapy projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of cancer immunotherapy projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the cancer immunotherapy market?
- Where is the cancer immunotherapy market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
- Our 286-page report provides 117 tables, 189 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
- In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), impact of rising Cancer Immunotherapy prices and recent developments.
Technology
- Monoclonal Antibodies
- Immunomodulators
- Other Technology
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Others
- Hospitals
- Cancer Research Centres
- Clinics
North America
- U.S.
- Canada
- Germany
- UK
- France
- Italy
- Spain
- Switzerland
- Netherlands
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- South East Asia
- Rest of Asia Pacific
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- GCC
- South Africa
- Egypt
- Rest of MEA
Leading companies profiled in the report
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GSK plc
- Immunocore Ltd.
- Johnson & Johnson Services, Inc.
- Lilly
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Company Limited
How will the Cancer Immunotherapy Market, 2024 to 2034 report help you?
In summary, our 280+ page report provides you with the following knowledge:
- Revenue forecasts to 2034 for Cancer Immunotherapy Market, 2024 to 2034, with forecasts for technology, application, end-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 25 key national markets – See forecasts for the Cancer Immunotherapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.
- Prospects for established firms and those seeking to enter the market – including company profiles for 16 of the major companies involved in the Cancer Immunotherapy Market, 2024 to 2034.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Cancer Immunotherapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..
The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.
Table of Contents
286 Pages
- 1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Cancer Immunotherapy Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
- 2 Executive Summary
- 3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.3 Impact Analysis
- 3.3.1 Market Driving Factors
- 3.3.1.1 Increasing Prevalence of Cancer
- 3.3.1.2 Increasing Research in Cancer Immunotherapy
- 3.3.1.3 Increasing Funding for the Cancer Research by Government, Public and Private Sector
- 3.3.2 Market Restraining Factors
- 3.3.2.1 Reimbursement Challenges for Cancer immunotherapy
- 3.3.2.2 High Cost and Side-effects of Cancer Immunotherapy
- 3.3.3 Market Opportunities
- 3.3.3.1 Increased Focus towards Advanced Treatment Protocols
- 3.3.3.2 Significant Unmet Need in Cancer Diagnosis
- 3.3.3.3 Growing use of AI in Cancer immunotherapy Manufacturing
- 3.4 Supply Chain Analysis
- 3.5 Regulatory Framework
- 3.6 Emerging Markets and Megatrends
- 3.7 Porter’s Five Forces Analysis
- 3.7.1 Bargaining Power of Buyers (High)
- 3.7.2 Bargaining Power of Suppliers (Low)
- 3.7.3 Threat of New Entrants (Low)
- 3.7.4 Threat of Substitute Products (High)
- 3.7.5 Intensity of Competitive Rivalry (High)
- 3.8 PEST Analysis
- 4 Cancer Immunotherapy Market Analysis by Technology
- 4.1 Key Findings
- 4.2 Technology Segment: Market Attractiveness Index
- 4.3 Cancer Immunotherapy Market Size Estimation and Forecast by Technology
- 4.4 Monoclonal Antibodies
- 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.4.2 Market Share by Region, 2024 & 2034 (%)
- 4.5 Immunomodulators
- 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.5.2 Market Share by Region, 2024 & 2034 (%)
- 4.6 Other Technology
- 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.6.2 Market Share by Region, 2024 & 2034 (%)
- 5 Cancer Immunotherapy Market by Application
- 5.1 Key Findings
- 5.2 Application Segment: Market Attractiveness Index
- 5.3 Cancer Immunotherapy Market, by Application
- 5.4 Lung Cancer
- 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.4.2 Market Share by Region, 2024 & 2034 (%)
- 5.5 Breast Cancer
- 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.5.2 Market Share by Region, 2024 & 2034 (%)
- 5.6 Colorectal Cancer
- 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.6.2 Market Share by Region, 2024 & 2034 (%)
- 5.7 Melanoma
- 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.7.2 Market Share by Region, 2024 & 2034 (%)
- 5.8 Prostate Cancer
- 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.8.2 Market Share by Region, 2024 & 2034 (%)
- 5.9 Head & Neck Cancer
- 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.9.2 Market Share by Region, 2024 & 2034 (%)
- 5.10 Ovarian Cancer
- 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.10.2 Market Share by Region, 2024 & 2034 (%)
- 5.11 Pancreatic Cancer
- 5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.11.2 Market Share by Region, 2024 & 2034 (%)
- 5.12 Others
- 5.12.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.12.2 Market Share by Region, 2024 & 2034 (%)
- 6 Cancer Immunotherapy Market by End-users
- 6.1 Key Findings
- 6.2 End-users Segment: Market Attractiveness Index
- 6.3 Cancer Immunotherapy Market by End-users Forecast, 2024-2034
- 6.4 Hospitals
- 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.4.2 Market Share by Region, 2024 & 2034 (%)
- 6.5 Cancer Research Centers
- 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.5.2 Market Share by Region, 2024 & 2034 (%)
- 6.6 Clinics
- 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.6.2 Market Share by Region, 2024 & 2034 (%)
- 7 Cancer Immunotherapy Market Analysis by Region
- 7.1 Key Findings
- 7.2 Regional Market Size Estimation and Forecast
- 8 North America Cancer Immunotherapy Market Analysis
- 8.1 Key Findings
- 8.2 North America Cancer Immunotherapy Market Attractiveness Index
- 8.3 North America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 8.4 North America Cancer Immunotherapy Market Size Estimation and Forecast by Country
- 8.5 North America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
- 8.6 North America Cancer Immunotherapy Market Size Estimation and Forecast by Application
- 8.7 North America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
- 8.8 U.S. Cancer Immunotherapy Market Analysis
- 8.9 Canada Cancer Immunotherapy Market Analysis
- 9 Europe Cancer Immunotherapy Market Analysis
- 9.1 Key Findings
- 9.2 Europe Cancer Immunotherapy Market Attractiveness Index
- 9.3 Europe Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 9.4 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Country
- 9.5 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Technology
- 9.6 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Application
- 9.7 Europe Cancer Immunotherapy Market Size Estimation and Forecast by End-users
- 9.8 Germany Cancer Immunotherapy Market Analysis
- 9.9 UK Cancer Immunotherapy Market Analysis
- 9.10 France Cancer Immunotherapy Market Analysis
- 9.11 Italy Cancer Immunotherapy Market Analysis
- 9.12 Spain Cancer Immunotherapy Market Analysis
- 9.13 Switzerland Cancer Immunotherapy Market Analysis
- 9.14 Netherlands Cancer Immunotherapy Market Analysis
- 9.15 Rest of Europe Cancer Immunotherapy Market Analysis
- 10 Asia Pacific Cancer Immunotherapy Market Analysis
- 10.1 Key Findings
- 10.2 Asia Pacific Cancer Immunotherapy Market Attractiveness Index
- 10.3 Asia Pacific Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 10.4 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Country
- 10.5 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Technology
- 10.6 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Application
- 10.7 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by End-users
- 10.8 Japan Cancer Immunotherapy Market Analysis
- 10.9 China Cancer Immunotherapy Market Analysis
- 10.10 India Cancer Immunotherapy Market Analysis
- 10.11 Australia Cancer Immunotherapy Market Analysis
- 10.12 South Korea Cancer Immunotherapy Market Analysis
- 10.13 South East Asia Cancer Immunotherapy Market Analysis
- 10.14 Rest of Asia Pacific Cancer Immunotherapy Market Analysis
- 11 Latin America Cancer Immunotherapy Market Analysis
- 11.1 Key Findings
- 11.2 Latin America Cancer Immunotherapy Market Attractiveness Index
- 11.3 Latin America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 11.4 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Country
- 11.5 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
- 11.6 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Application
- 11.7 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
- 11.8 Brazil Cancer Immunotherapy Market Analysis
- 11.9 Mexico Cancer Immunotherapy Market Analysis
- 11.10 Argentina Cancer Immunotherapy Market Analysis
- 11.11 Rest of Latin America Cancer Immunotherapy Market Analysis
- 12 MEA Cancer Immunotherapy Market Analysis
- 12.1 Key Findings
- 12.2 MEA Cancer Immunotherapy Market Attractiveness Index
- 12.3 MEA Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 12.4 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Country
- 12.5 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Technology
- 12.6 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Application
- 12.7 MEA Cancer Immunotherapy Market Size Estimation and Forecast by End-users
- 12.8 GCC Cancer Immunotherapy Market Analysis
- 12.9 South Africa Cancer Immunotherapy Market Analysis
- 12.10 Egypt Cancer Immunotherapy Market Analysis
- 12.11 Rest of MEA Cancer Immunotherapy Market Analysis
- 13 Company Profiles
- 13.1 Competitive Landscape, 2023
- 13.2 Strategic Outlook
- 13.3 F. Hoffmann-La Roche Ltd.
- 13.3.1 Company Snapshot
- 13.3.2 Company Overview
- 13.3.3 Financial Analysis
- 13.3.3.1 Net Revenue, 2019-2023
- 13.3.3.2 R&D, 2019-2023
- 13.3.3.3 Segment Market Shares, 2023
- 13.3.3.4 Regional Market Shares, 2023
- 13.3.4 Product Benchmarking
- 13.3.5 Strategic Outlook
- 13.4 Merck & Co., Inc.
- 13.4.1 Company Snapshot
- 13.4.2 Company Overview
- 13.4.3 Financial Analysis
- 13.4.3.1 Net Revenue, 2019-2023
- 13.4.3.2 R&D, 2019-2023
- 13.4.3.3 Segment Market Shares, 2023
- 13.4.3.4 Regional Market Shares, 2023
- 13.4.4 Product Benchmarking
- 13.4.5 Strategic Outlook
- 13.5 Novartis AG
- 13.5.1 Company Snapshot
- 13.5.2 Company Overview
- 13.5.3 Financial Analysis
- 13.5.3.1 Net Revenue, 2019-2023
- 13.5.3.2 R&D, 2019-2023
- 13.5.3.3 Segment Market Shares, 2023
- 13.5.3.4 Regional Market Shares, 2023
- 13.5.4 Product Benchmarking
- 13.5.5 Strategic Outlook
- 13.6 Bristol-Myers Squibb Company
- 13.6.1 Company Snapshot
- 13.6.2 Company Overview
- 13.6.3 Financial Analysis
- 13.6.3.1 Net Revenue, 2019-2023
- 13.6.3.2 R&D, 2019-2023
- 13.6.3.3 Segment Market Shares, 2023
- 13.6.3.4 Regional Market Shares, 2023
- 13.6.4 Product Benchmarking
- 13.6.5 Strategic Outlook
- 13.7 Bayer AG
- 13.7.1 Company Snapshot
- 13.7.2 Company Overview
- 13.7.3 Financial Analysis
- 13.7.3.1 Net Revenue, 2019-2023
- 13.7.3.2 R&D, 2019-2023
- 13.7.3.3 Segment Market Shares, 2023
- 13.7.3.4 Regional Market Shares, 2023
- 13.7.4 Product Benchmarking
- 13.7.5 Strategic Outlook
- 13.8 AstraZeneca
- 13.8.1 Company Snapshot
- 13.8.2 Company Overview
- 13.8.3 Financial Analysis
- 13.8.3.1 Net Revenue, 2019-2023
- 13.8.3.2 R&D, 2019-2023
- 13.8.3.3 Segment Market Shares, 2023
- 13.8.3.4 Regional Market Shares, 2023
- 13.8.4 Product Benchmarking
- 13.8.5 Strategic Outlook
- 13.9 Lilly
- 13.9.1 Company Snapshot
- 13.9.2 Company Overview
- 13.9.3 Financial Analysis
- 13.9.3.1 Net Revenue, 2019-2023
- 13.9.3.2 R&D, 2019-2023
- 13.9.3.3 Regional Market Shares, 2023
- 13.9.4 Product Benchmarking
- 13.9.5 Strategic Outlook
- 13.10 Pfizer Inc.
- 13.10.1 Company Snapshot
- 13.10.2 Company Overview
- 13.10.3 Financial Analysis
- 13.10.3.1 Net Revenue, 2019-2023
- 13.10.3.2 R&D, 2019-2023
- 13.10.3.3 Segment Market Shares, 2023
- 13.10.3.4 Regional Market Shares, 2023
- 13.10.4 Product Benchmarking
- 13.10.5 Strategic Outlook
- 13.11 Johnson & Johnson Services, Inc.
- 13.11.1 Company Snapshot
- 13.11.2 Company Overview
- 13.11.3 Financial Analysis
- 13.11.3.1 Net Revenue, 2019-2023
- 13.11.3.2 R&D, 2019-2023
- 13.11.3.3 Segment Market Shares, 2023
- 13.11.3.4 Regional Market Shares, 2023
- 13.11.4 Product Benchmarking
- 13.11.5 Strategic Outlook
- 13.12 GSK plc
- 13.12.1 Company Snapshot
- 13.12.2 Company Overview
- 13.12.3 Financial Analysis
- 13.12.3.1 Net Revenue, 2019-2023
- 13.12.3.2 R&D, 2019-2023
- 13.12.3.3 Segment Market Shares, 2023
- 13.12.3.4 Regional Market Shares, 2023
- 13.12.4 Product Benchmarking
- 13.12.5 Strategic Outlook
- 13.13 Gilead Sciences, Inc.
- 13.13.1 Company Snapshot
- 13.13.2 Company Overview
- 13.13.3 Financial Analysis
- 13.13.3.1 Net Revenue, 2019-2023
- 13.13.3.2 R&D, 2019-2023
- 13.13.3.3 Segment Market Shares, 2023
- 13.13.3.4 Regional Market Shares, 2023
- 13.13.4 Product Benchmarking
- 13.13.5 Strategic Outlook
- 13.14 Amgen Inc.
- 13.14.1 Company Snapshot
- 13.14.2 Company Overview
- 13.14.3 Financial Analysis
- 13.14.3.1 Net Revenue, 2019-2023
- 13.14.3.2 R&D, 2019-2023
- 13.14.3.3 Regional Market Shares, 2023
- 13.14.4 Product Benchmarking
- 13.14.5 Strategic Outlook
- 13.15 AbbVie Inc.
- 13.15.1 Company Snapshot
- 13.15.2 Company Overview
- 13.15.3 Financial Analysis
- 13.15.3.1 Net Revenue, 2019-2023
- 13.15.3.2 R&D, 2019-2023
- 13.15.3.3 Segment Market Shares, 2023
- 13.15.3.4 Regional Market Shares, 2023
- 13.15.4 Product Benchmarking
- 13.15.5 Strategic Outlook
- 13.16 Immunocore Ltd.
- 13.16.1 Company Snapshot
- 13.16.2 Company Overview
- 13.16.3 Financial Analysis
- 13.16.3.1 Net Revenue, 2019-2023
- 13.16.3.2 R&D, 2019-2023
- 13.16.3.3 Regional Market Shares, 2023
- 13.16.4 Product Benchmarking
- 13.16.5 Strategic Outlook
- 13.17 Sanofi
- 13.17.1 Company Snapshot
- 13.17.2 Company Overview
- 13.17.3 Financial Analysis
- 13.17.3.1 Net Revenue, 2019-2023
- 13.17.3.2 R&D, 2019-2023
- 13.17.3.3 Segment Market Shares, 2023
- 13.17.3.4 Regional Market Shares, 2023
- 13.17.4 Product Benchmarking
- 13.17.5 Strategic Outlook
- 13.18 Takeda Pharmaceutical Company Limited.
- 13.18.1 Company Snapshot
- 13.18.2 Company Overview
- 13.18.3 Financial Analysis
- 13.18.3.1 Net Revenue, 2019-2023
- 13.18.3.2 R&D, 2019-2023
- 13.18.3.3 Segment Market Shares, 2023
- 13.18.3.4 Regional Market Shares, 2023
- 13.18.4 Product Benchmarking
- 13.18.5 Strategic Outlook
- 14 Conclusion and Recommendations
- 14.1 Concluding Remarks from Visiongain
- 14.2 Recommendations for Market Players
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.